‘부시라민’ 3상 DSMB 결과 ‘임박’…리바이브, 경동·종근당의 주목을 받아

The Data Safety and Monitoring Board (DSMB) of the US Food and Drug Administration (FDA) is set to conduct an interim analysis of Revive Therapeutics’ global phase 3 clinical trial of Bucillamine for COVID-19, with the meeting scheduled for the 10th of August. Revive is expected to announce the recommendation of the DSMB by the 17th of August. The company is specializing in developing treatments f …